SGLT2 inhibitors and the risk of diabetic ketoacidosis

Practical Diabetes

Volumn 32, Issue 7, 2015, Pages 263-264a

  Redford, Christopher ^a   Doherty, Laura ^a   Smith, Jamie ^a  

^a TORBAY AND SOUTH DEVON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

dapagliflozin; diabetes; ketoacidosis; SGLT2

Indexed keywords

BIPHASIC INSULIN; DAPAGLIFLOZIN; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; ISOPHANE INSULIN; METFORMIN; RECOMBINANT HUMAN INSULIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ADULT; ARTICLE; CASE REPORT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; MEDICAL HISTORY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; RISK ASSESSMENT; RISK FACTOR;

EID: 84952057112     PISSN: 20472897     EISSN: 20472900     Source Type: Journal    
DOI: 10.1002/pdi.1969     Document Type: Article

References (5)

1. Bailey CJ, et al., Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375 (9733): 2223-33.
2. Wilding JP, et al., Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156 (6): 405-15.
3. FDA safety alert, 15 May 2015. ' FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood.'
4. Suzuki M, et al., Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes 2014; 4:e125.
5. Perkins B, et al., Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes. Diabetes Care 2014; 37 (5): 1480-3.